Literature DB >> 2266549

Psychotropic drugs and mental retardation: 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings.

D J Clarke1, S Kelley, K Thinn, J A Corbett.   

Abstract

The Birmingham Special Needs Register, a computerized database, was used to examine the disabilities of, and the use of psychoactive (psychotropic and antiepileptic) drugs among 1825 people over the age of 20 with mental retardation. People living in three different types of residential setting (hospitals, community residential facilities and family homes) were compared. The prevalence of physical disability, impaired communication and incontinence was highest among people resident in hospital, followed by those living with their families. People resident in community residential facilities were the least disabled group. Psychotropic drugs prescribed to alter behaviour were used most frequently in hospitals (prescribed for 40.2% of people), followed by community residential facilities (19.3%). Use was lowest in family homes (10.1%). Most hospital residents who received medication to alter behaviour did not have a diagnosed psychiatric disorder. The reported prevalence of behaviour disorders among the three populations was not significantly different. Drugs for epilepsy were prescribed for 26.2% of hospital residents, 9.3% of people in community residential facilities and 18.5% of people living with their families.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2266549     DOI: 10.1111/j.1365-2788.1990.tb01549.x

Source DB:  PubMed          Journal:  J Ment Defic Res        ISSN: 0022-264X


  8 in total

1.  International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities.

Authors:  Shoumitro Deb; Henry Kwok; Marco Bertelli; Luis Salvador-Carulla; Elspeth Bradley; Jennifer Torr; Jarret Barnhill
Journal:  World Psychiatry       Date:  2009-10       Impact factor: 49.548

2.  Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study.

Authors:  John A Tsiouris; Soh-Yule Kim; W Ted Brown; Jill Pettinger; Ira L Cohen
Journal:  J Autism Dev Disord       Date:  2013-03

Review 3.  Neuroleptics, learning disability, and the community: some history and mystery.

Authors:  D Manchester
Journal:  BMJ       Date:  1993-07-17

4.  Inter-Rater Reliability of the Diagnoses of Psychosis and Depression in Individuals with Intellectual Disabilities.

Authors:  S Einfeld; B Tonge; L Chapman; C Mohr; J Taffe; S Horstead
Journal:  J Appl Res Intellect Disabil       Date:  2007-09

Review 5.  A review of empirical evidence of somatic treatment options for the MI/DD population.

Authors:  Thaddeus P Ulzen; Richard E Powers
Journal:  Psychiatr Q       Date:  2008-08-23

6.  Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice.

Authors:  Carol Paton; Sumera Bhatti; Kiran Purandare; Ashok Roy; Tre Barnes
Journal:  BMJ Open       Date:  2016-12-05       Impact factor: 2.692

7.  Short-term PsychoEducation for Carers To Reduce Over Medication of people with intellectual disabilities (SPECTROM): study protocol.

Authors:  Shoumitro Deb; Bharati Limbu; Mike Crawford; Tim Weaver
Journal:  BMJ Open       Date:  2020-04-08       Impact factor: 2.692

8.  De-Prescribing of Psychotropic Medications in the Adult Population with Intellectual Disabilities: A Commentary.

Authors:  Bernadette Flood
Journal:  Pharmacy (Basel)       Date:  2018-03-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.